PSI met an interim enrollment milestone of 450 randomized pediatric patients in a phase III study of a novel antiemetic used for the prevention of postoperative nausea and vomiting (PONV).
PSI reached an interim enrollment target of 150 randomized patients in a phase II study of a novel antineoplastic agent in pancreatic cancer.
PSI met an interim enrollment target of 300 randomized patients in a phase III study of a novel biological agent in multiple myeloma.
PSI completed the active treatment period in a phase II study of a novel combination product in patients with asthma.
PSI completed a phase II study of a novel biological agent in patients with renal cell carcinoma.
